Literature DB >> 10403855

The biology of chronic myeloid leukemia.

S Faderl1, M Talpaz, Z Estrov, S O'Brien, R Kurzrock, H M Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10403855     DOI： 10.1056/NEJM199907153410306

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  254 in total

1.  Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.

Authors:  Yuka Hirose; Hitoshi Kiyoi; Masanori Iwai; Toshiya Yokozawa; Masafumi Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain.

Authors:  G Radziwill; R A Erdmann; U Margelisch; K Moelling
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

3.  p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Afsar A Mian; Anna Metodieva; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

5.  First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.

Authors:  Claudia Vener; Rita Banzi; Federico Ambrogi; Annalisa Ferrero; Giuseppe Saglio; Gabriella Pravettoni; Milena Sant
Journal:  Blood Adv       Date:  2020-06-23

6.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 7.  Current developments in molecular monitoring in chronic myeloid leukemia.

Authors:  Justine Ellen Marum; Susan Branford
Journal:  Ther Adv Hematol       Date:  2016-07-15

8.  Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.

Authors:  Hai-Xia Wang; Heng Xiao; Liang Zhong; Kun Tao; Ya-Juan Li; Shi-Feng Huang; Jian-Ping Wen; Wen-Li Feng
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

9.  Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.

Authors:  Ming-Huang Chen; Tzeon-Jye Chiou; Peng-Chan Lin; Jyh-Pyng Gau; Hui-Chi Hsu; Liang-Tsai Hsiao; Jin-Hwang Liu; Po-Min Chen
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

Review 10.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.